Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Effects of corneal sub-basal nerve fiber length on the response to treatment in dry eye syndrome

Poster Details

First Author: M.Shoja IRAN

Co Author(s):    S. Salimpoor                    

Abstract Details


To estimate whether levels of corneal subbasal nerve fiber length (SNFL) in dry eye Syndrome (DES) could predict the level of improvement in signs and symptoms after treatment.


This prospective randomized, single-masked, clinical trial was conducted with 60 patients with DES who were randomized into 3 treatment groups (preservative free artificial tear, Loteprednole and Cyclosporine 0.05%) for 6 weeks.


At baseline, in vivo confocal microscopy of central cornea was performed in both eyes. Patients with DES were divided into 2 subgroups, those with low baseline SNFL and those with near-normal baseline SNFL (the cut-off point: the median of SNFL ). Clinical signs and symptoms at baseline and after 6 weeks of treatment were compared between the subgroups with low and near-normal SNFL for all therapeutic groups Main Outcome Measures OSDI questionnaires, corneal fluorescein staining (CFS), tear break-up time, Schirmer’s test, and SNFL.


In the artificial tear and cyclosporine groups, although no significant improvement in any sign or symptom was noted in patients with low baseline SNFL, subjects with near-normal baseline SNFL showed significant improvement in both symptoms and corneal fluorescein staining (CFS) score (all P<0.05). In the loteprednol group, no significant change was apparent for any sign or symptom in either subgroup of low or near-normal baseline SNFL.


Significant improvements in CFS and patient symptoms after DES treatment were apparent in the subgroup with near-normal corneal SNFL. Consideration of SNFL may thus assist in explaining the unpredictability of patients’ response to DES treatment.

Financial Disclosure:


Back to Poster listing